Boston Scientific Stock News

MARLBOROUGH, Mass. , Sept. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Tuesday, September 30, 2025, beginning at 8:30 a.m.

For biotech firms, a bit of positive news—a key result from clinical trials or new drug discovery, say—can be the difference between a major rally based on a path toward sustained profitability and a slump that can lead to the firm's eventual demise.

As tech stocks float at historic highs, it's a good time to look elsewhere for growth. A Citi screen turned up eight names that are mostly outside the tech sector.

Uber, JPMorgan and RTX are stocks to watch. The market jumped Friday as Fed chief Powell hinted at rate cuts.

Boston Scientific is a 'forever stock' due to management foresight, robust R&D, and leadership in AI-driven medical devices. Despite a weak valuation grade, its strong financials, global expansion, and AI integration justify a long-term buy rating. Key risks include regulatory changes, insider selling, and potential revenue impacts from federal healthcare cutbacks; buy on dips is advised.

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divestiture of non-core assets, new leadership, and a focus on high-growth hospital monitoring technologies. Eli Lilly remains a core holding due to its leadership in diabetes and obesity treatments, robu...

LONDON & BOSTON--(BUSINESS WIRE)--Keyron appoints former FDA and Boston Scientific leaders as ForePass—a breakthrough device for severe metabolic disease—prepares for clinical trials.

Boston Scientific (BSX -0.17%), a leading medical device maker known for its heart and surgical products, released second-quarter results on July 23, 2025. Revenue reached $5.06 billion for Q2 2025, beating analyst estimates of $4.89 billion.